by Nathaniel Harding | Feb 1, 2024 | Blog
2023 Lookback for Cortado Ventures At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and most innovative startups. Let’s...
by Nathaniel Harding | Jan 4, 2024 | Blog
Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ — Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on...
by Nathaniel Harding | Nov 2, 2023 | Blog
At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi...
by Nathaniel Harding | Oct 11, 2023 | Blog
FOR IMMEDIATE RELEASE Oct. 11, 2023 Contact: Anthony Triana atriana@saxum.com (Direct) 405.818.0791 Cortado Ventures Invests in Teren, Inc.: Advancing Data-Driven Solutions for Climate and Terrain Risk Assessment OKLAHOMA CITY – Cortado Ventures, an early-stage...
by Nathaniel Harding | Sep 25, 2023 | Blog
AltAssets: Hefty exits help Cortado Ventures score huge fund size increase for sophomore raise Wall Street Journal VC Pro: VC Daily: What the New IPOs Mean for Late-Stage Market; Instacart Pops StrictlyVC: Musk gets probed, Neuralink searches for recruits, and...
by Nathaniel Harding | Sep 18, 2023 | Blog
Contact: Kelly Vogt Campbell kvogtcampbell-ext@saxum.com (Direct) 310.927.4537 Sept. 18, 2023 Cortado Ventures Starting Final Close for Fund II Oversubscribed at $80M Midcontinent VC firm brings total AUM to over $110M in less than three years; four-times increase...
